RANGER II SFA: 2-Year Results Show Benefits of Ranger DCB | Dr Ravish Sachar

Watch the full video on Radcliffe Vascular here: www.radcliffevascular.com/vid...
In this video interview, Dr Ravish Sachar (North Carolina Heart & Vascular, Raleigh, NC, US) discusses the 2-year outcomes of the RANGER II SFA Global Study, originally presented at VIVA 2021. Outcomes suggest that patients treated with the Ranger™ drug-coated balloon (Boston Scientific) benefited from improved primary patency and greater freedom from target lesion revascularisation compared to those treated with uncoated balloon PTA.
Questions:
1. What was the device investigated in this trial?
2. What was the study design and the patient cohort?
3. What are your key findings?
4. In what instances would you suggest the use of this DCB?
5. What are your key take-home messages?
Recorded Remotely from Raleigh, 2021.
Editor: Mirjam Boros
Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.